Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OPGN $NVS Sandoz collaboration extended to Jan 2025.
Sandoz (Novartis sub) CEO Richard Saynor: "As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat (AMR). This collaboration (with OpGen’s subsidiary Ares Genetics) is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets."
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
https://finance.yahoo.com/news/opgen-subsidiary-ares-genetics-provides-113000156.html
Novartis (NVS) Market cap: US$203.15 Billion as of April 2022.
Why would one of world's largest pharmaceutical firms form a key partnership with little OPGEN unless OPGEN had what Novartis needed?
OPGN
OpGen Inc
0.6705
0.0478 (7.68%)
Volume: 176,579
Day Range: 0.63 - 0.69
Bid: 0.67
Ask: 0.682
Last Trade Time: 10:20:47 AM EDT
Total Trades: 341
there ve go mick, .69 again sanks to Yi Chen
OPGN
OpGen Inc
0.65
0.0443 (7.31%)
Volume: 16,183
Bid: 0.6105
Ask: 0.65
Last Trade Time: 9:20:03 AM EDT
Total Trades: 56
OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
OPGN
OpGen, Inc.
Wed, April 20, 2022, 7:30 a.m.
OpGen, Inc.
OpGen, Inc.
New services include pathogen identification, microbiome profiling and rapid turnaround sequencing of clinical isolates
ROCKVILLE, Md., April 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), is commercially launching a series of new genome sequencing and analysis services globally.
In March 2022, the WHO emphasized the critical importance of microbial genome sequencing for pandemic preparedness in its new 10-year strategy1 for the global genomic surveillance of pathogens with pandemic and epidemic potential. To help curb the global spread of antimicrobial resistance (AMR) pathogens, Ares Genetics is expanding its commercial offering of sequencing and analysis services aimed at clinical microbiologists and specialists in public health and infection prevention and control. The new services include ARESid and ARESiss Express.
ARESid enables accurate and comprehensive detection and surveillance of bacterial and fungal microbes in a culture-free fashion directly from native patient specimen or environmental samples. Due to the semi-quantitative nature of ARESid, the sequencing and analysis service is equally suitable for pathogen detection and for microbiome profiling applications.
ARESiss Express accelerates the company’s well-established platform for whole genome sequencing of clinical isolates. “We are delighted to respond to customer demand by introducing ARESiss Express,” said Dr. Arne Materna, CEO of Ares Genetics. “ARESiss Express builds on our clinically validated platform for whole genome sequencing of bacterial isolates but reduces turnaround times from ARESiss by more than 80% to five business days in order to enable microbiologists and epidemiologists to analyze and respond to local outbreaks in a timely manner.”
ARESiss Express reports include outbreak relevant information - for instance on pathogen identity and type - as well as actionable information on AMR, thanks to the company’s proprietary technology enabling the AI-powered prediction of antibiotic susceptibility and resistance directly from genomic data for a wide range of pathogen drug combinations.
ARESid and ARESiss Express sequencing results are accessible to customers via AREScloud, a web application for which the company plans to release a number of new features over the coming months.
Customers can submit orders for both sequencing services, to be performed at Ares Genetics’ service laboratory in Vienna, Austria. U.S.-based sequencing services will be launched later this year
Customers looking to enhance their data interpretation pipelines can access the AREScloud platform immediately by subscription to the service.
All Ares Genetics products and services are for research use only.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
OpGen Inc (OPGN)
0.8501 ? 0.0022 (0.26%)
Volume: 158,083 @03/11/22 5:59:18 PM EST
Bid Ask Day's Range
0.837 0.91 0.82 - 0.865
OPGN Detailed Quote
This biotech is almost ready. FDA approval, product play almost set.
Buy the dips.
OpGen Inc (OPGN)
0.89 ? 0.0006 (0.07%)
Volume: 128,653 @02/04/22 7:38:11 PM EST
Bid Ask Day's Range
0.88 0.92 0.880101 - 0.9494
OPGN Detailed Quote
OpGen Inc (OPGN)
0.89 ? 0.0006 (0.07%)
Volume: 128,653 @02/04/22 7:38:11 PM EST
Bid Ask Day's Range
0.88 0.92 0.880101 - 0.9494
OPGN Detailed Quote
Bounce on 01-27? Edison, London Exchange, TaylorWessing partnering in a 3-day global presentation Jan 25-27. OpGen AI & biotechnology are in the spotlight tomorrow in the context high-profile awareness of multidrug-resistant microorganisms (MDROs)--a surging pandemic more deadly than Covid. Just recently, it was announced that a strain of gonorrhea, a superbug immune to any and all antibiotic drugs, has reached the USA.
$OPGN
"We harness the power of molecular microbiology and bioinformatics to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and help improve antibiotic stewardship."
Headquartered in Rockville, Maryland, OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes.
Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR).
By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).
$OPGN Coming up Tuesday Jan 25: OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
https://ir.opgen.com/news-releases/news-release-details/opgen-participate-edison-groups-global-healthcare-open-house
ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.
The three-day event, in association with London Stock Exchange, global law firm Taylor Wessing and OpenExchange, will take place between 25th-27th January, focusing on 33 companies. Day one will feature businesses within pharmaceuticals & drug discovery, day two focuses on AI & technology in healthcare, while businesses adopting new approaches to hard-to-solve problems will round off the event.
Content will be available to stream from January 25th on Edison’s website and OpenExchange.tv. Attendance is free and anyone wanting to attend can sign up here:
https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/
For more information on the event and details on how to register, please see below.
Edison Group:
Global Healthcare Open House Conference 2022
Date: January 25-27th, 2022
Edison Group Open House Registration
Presentation information: The company presentation will be available on demand on www.edisongroup.com beginning at 7am ET on Thursday, January 27th. The presentation will also be available on OpGen’s investor relations page.
$OPGN Marketbeat: "The main competitors of OpGen include Laboratory Co. of America, Quest Diagnostics, Guardant Health, Natera, Invitae, CareDx, Veracyte, Fulgent Genetics, RadNet, and Burning Rock Biotech."
Is lab giant Quest Diagnostics $DGX (MC US$17.03 Billion) the dark horse here? Quest snapping up competitor OpGen, Inc and its subsidiaries, patents (IP), and substantial cash hoard (larger than OPGN MC) for the Quest equivalent of minor cash would be smart now that Quest has recently formed partnerships with Wal-Mart and Safeway in-store health clinics for laboratory testing and is the laboratory provider to UnitedHealthcare with its 46 million members. Quest gets OpGen for their on-site automated rapid detection (and early warning) of dangerous pathogens (replacing dated lab culture methods) and detection of antibiotic resistance to drugs typically prescribed by health providers.
https://www.marketbeat.com/stocks/NASDAQ/OPGN/competitors-and-alternatives/
Some of this doubtless is tax loss selling: For information on that subject, see:
https://www.firstrepublic.com/-/media/frb/documents/pdfs/year-end-planning/2021-important-tax-deadlines-dates.pdf
$OPGN
Can't believe that I am the only 1 posting, this is getting good up in here LOL
$OPGN
Looks like they might finally let her run........
Been a great day so far either way, run coming soon
$OPGN
RSI is at 19..........the pop here is going to be gigantic LOL
$OPGN
Looks good for next week. RSI oversold, good earnings, triple bottom bounce
$OPGN
OpGen Inc (OPGN)
1.72 ? -0.05 (-2.82%)
Volume: 1,145,584 @11/05/21 7:58:27 PM EDT
Bid Ask Day's Range
1.72 1.75 1.7 - 1.7699
OPGN Detailed Quote
I don't think it's ever a good thing.....
Increasing AS. Not good for investors.
If they increase the AS, and stipulate that the OS will not increase, that would be OK.
$OPGN Commercial launch of unique AREScloud app. Uses superior whole genome sequencing (WGS).
Snippets Oct 21 PR. Ares Genetics is wholly owned OPGN subsidiary.
"Leading global health organizations have acknowledged the importance of whole genome sequencing (WGS) of bacterial isolates for effective surveillance and infection prevention and control."
"AREScloud is designed to help clinical microbiologists, epidemiologists and IPC experts overcome this challenge. The software fully automates data processing - from raw sequence data to report - and offers insights into epidemiologically and etiologically relevant information including pathogen identity, genotype, virulence, plasmids, and AMR (anti-microbial resistance)."
"In addition to generating individual sample reports, the AREScloud version that has now been commercially released for the first time introduces unique features for comparative and outbreak analysis."
Ares Genetics is actively engaged in discussions with clinical expert users and is collaborating with two major U.S. hospitals.
https://ih.advfn.com/stock-market/NASDAQ/opgen-OPGN/stock-news/86338872/opgen-subsidiary-ares-genetics-launches-arescloud
https://www.ares-genetics.cloud/auth/login?redirect=%2Fhome
https://www.ares-genetics.com/diagnostics
ST heavily bearish, often a bullish sign. Time will tell.
On Oct 18, 2021, Opgen closed its direct offering with a single institutional investor of 150,000 shares of convertible preferred stock and warrants to purchase up to 7,500,000 shares of common stock for gross proceeds of $15 million. The shares of preferred "are convertible into an aggregate of 7,500,000 shares of common at a conversion price of $2.00 per share at any time after the Company has received shareholder approval to increase the number of authorized shares of common stock of the Company."
That approval is expected at upcoming special shareholders' meeting that the Board yesterday set for December 8, 2021. Opgen got the $15 million for the preferred, but any conversion to common shares has to wait until then.
The Board had discretion to hold the meeting as early as Oct 29 or as late as Dec 17 (18-19 weekend) according to Delaware bylaws. They chose to stetch it out to a point right before holidays kick into gear. Why the unusually long delay for a special (read: pressing) shareholders meeting? Are CEO Schacht and Chairman Rhodes anticipating something bullish to take place in the 50 day interval?
https://ih.advfn.com/stock-market/NASDAQ/opgen-OPGN/stock-news/86311767/opgen-announces-closing-of-15-million-registered
Silver lining in timing of meeting? The special shareholders' meeting has been set by the Board for December 8, 2021, a full 50 days after the record date of October 19, 2021.
OpGen is a Delaware corporation. By Delaware bylaws, the record date must fall within 10 to 60 days before any shareholder meeting. The special (read: "we really need this you b's") meeting could have been set for Oct 29th at the earliest or Dec 19th at the latest.
If it's so pressing to get this done, why are CEO Schacht and Chairman Rhodes dawdling? A plausible explanation is they need more "wait and see" time because something is cooking, something that could happily and profitably relieve them of all this rigmarole and the authorizing of new shares.
Delaware
§ 222. Notice of meetings and adjourned meetings.
"(b)Unless otherwise provided in this chapter, the notice of any meeting shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting."
OpGen shares are trading higher after the company announced it received FDA clearance for Acuitas AMR gene panel. The company also provided a business update and announced preliminary unaudited revenue and cash position for Q3.
OPGN
OpGen Inc (OPGN)
3.11 ? -0.09 (-2.81%)
Volume: 810,925 @09/22/21 7:32:22 PM EDT
Bid Ask Day's Range
3.1 3.15 3.04 - 3.2
OPGN Detailed Quote
Bull mania crushed, catching some shares at these levels mightn't be such a bad idea. Second guessing the FDA or Oliver Schacht? Not recommended.
Some serious selling. Green again.
Price takes major hits, but always comes back. Sellers have to sell at the low of the day. Wish I was buying more today. Holding pat for awhile.
Up and green - again.
Looks like we are heading higher.
430K shares in the 1st 30 minutes.
Some serious selling along with some serious buying. Gotta love it.
Picked up some more today.
Just bought a few at 3.67. The selling this morning was very strong, but we held the recent gains and are now heading north again.
Three points why I like this investment:
1) They could have increased the AS a few months ago, but chose not to.
2) They recently beat the analysts' earnings projections.
2) The FDA is ready to approve this technology.
In June, we submitted an updated 510(k) summary to the FDA for our Acuitas AMR Gene Panel for isolates. The FDA had previously provided substantive feedback on what we believe is all key documents, including the package insert, electronic user guide and operator manual, in line with their currently expected timeline of doing so by the end of May. The FDA recently reiterated to us that it intends to complete its review by the end of August of 2021.
Since submitting our revised documents to the FDA, we have not received any additional feedback nor questions or requests for additional information. Although the FDA clarified that their timelines can be affected by various factors, we're confident in the progress moving us much closer towards reaching a final FDA clearance decision point in the coming weeks based on the FDA's current expected timeline.
You do not understand.
The FDA is ready to approve this technology. Of course it is not yet ready for sales and distribution - yet.
In June, we submitted an updated 510(k) summary to the FDA for our Acuitas AMR Gene Panel for isolates. The FDA had previously provided substantive feedback on what we believe is all key documents, including the package insert, electronic user guide and operator manual, in line with their currently expected timeline of doing so by the end of May. The FDA recently reiterated to us that it intends to complete its review by the end of August of 2021.
Since submitting our revised documents to the FDA, we have not received any additional feedback nor questions or requests for additional information. Although the FDA clarified that their timelines can be affected by various factors, we're confident in the progress moving us much closer towards reaching a final FDA clearance decision point in the coming weeks based on the FDA's current expected timeline.
Blindly ignored by the narratives pumped elsewhere, the newly fashioned company website (put up yesterday) still appends this disclaimer:
"For Research Use Only. Not for use in diagnostic procedures."
https://www.opgen.com/acuitas-tests/amr-gene-panel/
https://www.opgen.com/acuitas-lighthouse/
Meanwhile, a login page is just that, a login page. It's not the goods as they would purport it.
Appears to be that way.
The volume confirms the real interest. Something very good is going on.
Do not understand your post.
Makes no sense.
S-twits reliable barometer so far. When they go batcrazy over the top in pumping the stock, take some easy profits and generally proceed with caution. When bears take over that board, increase holdings. Right now there's an army of hysterical bulls and cheerleaders urging buy more, buy more and egging on newbies; the chorus repeating themselves ad nauseam. Scale of 1 to 10, 9.8. Be wary if chasing this one. Company will ATM out of the blue into strength.
My 2cents plain.
Good day. Just checked and
no NEWS on the FDA approval. I assume that is what is pushing this. Wish I had thousands more $$$, I would load up here. I'm in as deep as I can for now.
Waiting for the NEWS on the FDA
approval, and a target of $7 - $10 in the near future.
LoL Miller Time!
In June, The FDA committed to responding
to their application before the end of August. The FDA had no unaddressed issues or concerns at that time. Maybe folks know the approval is coming today. Am going to pick up a few more now.
Added more in premarket.
Volume gives me optimism.
3 years ago, this was $40.
That would be a great target. They had a meeting in July to increase the AS. It was adjourned and, in August, they decided against adding more AS. Now, we see the spike in price.
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2719
|
Created
|
07/29/15
|
Type
|
Free
|
Moderators |
Vexing problems oftimes lead to creative solutions. OpGen's robust ingenuity is a case in point.
Problem: "Antibiotic resistance is a global threat. There is no system in place to track antibiotic resistance globally. Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats." -U.S. Center for Disease Control
Enter OpGen, Inc. Press Releases
OpGen, Inc. (Gaithersburg, MD, USA) (Nasdaq OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to guide clinicians with rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDRO). Subsidiaries include Curetis GmbH and
Ares Genetics GmbH*. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI. Learn more
OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, PNA FISH, Quick Fish, Acuitas® Lighthouse, and the ARES Technology Platform. The Ares Technology Platform includes ARESdb (db=database) that uses NGS (next generation sequencing) technology and AI-powered bioinformatics solutions to predict antibiotic response (resistance). Artificial intelligence based DNA testing revolutionizes infectious disease diagnostics and therapeutics.* Patient outcomes improved; costs reduced. Learn more
"Time is of the essence in cases of severe infections, not infrequently a question of life or death, and knowing what not to prescribe is as important as knowing what to prescribe."
OpGen Corporate Overview 06-Oct-2020 (Recommended viewing)
*02Oct2020 OpGen's wholly owned Ares Genetics GmbH* (Vienna) won the Austria State Prize for innovation with their Project "ARESupa- Molecular Antibiotic Resistance Diagnostics using Artificial Intelligence - With a (Ares Genetics) universal pathogen test, antibiotic resistance from germs can be predicted quickly and accurately."
OpGen subsidiary Ares Genetics, which combines Next Generation Sequencing (NGS) with ARESdb, is the world‘s most comprehensive database on the genetics of antibiotic resistance. ARESdb is also the world’s largest database of genetic antibiotic resistance markers and predictive AMR panels. ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally. ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with ~98% accuracy. ARESdb covers 30 years of emerging antibiotic resistance to accurately detect AMR and combines deep whole-genome sequencing data with antibiotic resistance profiles continuously expanded. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI.
Fast & Simple Syndromic Testing for Severe Infections -- Improving Patient Outcomes
Detects pathogens rapidly, including associated antibiotic resistance genes
Antibiotic resistant microorganisms are a global health threat (Per CDC, WHO, US GAO)
Our UNYVERO A50 IS FDA APPROVED UNYVERO FLYER (Recommended viewing)
With the Unyvero A50 Solution, OPGen's wholly owned subsidiary Curetis has developed a molecular diagnostics system for reliable and extremely rapid diagnosis of severe infectious diseases in under 5 hours versus up to 96 hours using current methods. The system uses powerful multiplex PCR technology and syndromic testing to detect a wide variety of microorganisms, antibiotic resistance markers, or toxins.
Unyvero A50 Applications for Major Infectious Disease
HPN- Hospitalized Pneumonia
HPN Solution
BCU — Blood Culture
Analyzes the DNA of 103 pathogens & resistance genes from a
positive blood culture for fast diagnostics of blood stream infections.
BCU Solution
IAI — Intra-Abdominal Infection
IAI Solution
UTI — Urinary Tract Infection
Unyvero A50 System
Unyvero A50 Cartridge
Applications
Unyvero A30 RQ in development
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |